In the wake of many researchers and pharma giants across the globe upping their game to come up with a potential vaccine to cure the pandemic, Bharat Biotech announced that the Animal trials in Phase I clinical trials are quite impressive.
The drug development firm headquartered in Hyderabad took to Micro-blogging site Twitter and said they are proud to announce the results of the animal trials of the COVAXIN.
âBharat Biotech proudly announces the animal study results of COVAXIN - These results demonstrate the protective efficacy in a live viral challenge model,â the firm's Tweet read.
Bharat Biotech and the Indian Council of Medical Research (ICMR) joined hands to manufacture a vaccine named COVAXIN. 12 Institutions across India were picked to carry out the clinical trials.
To get accurate data on the efficiency of the vaccine, Bharat Biotech International Limited has picked twenty macaques for the Animal trials. These macaques were divided into four groups with five macaques in each group.
It is believed that the vaccine candidate has resulted in generating robust immune system. The system helps in preventing the infection of the virus.
On the other hand, the pandemic vaccine was given to ten more volunteers in Nizam's Institute of Medical Sciences - [NIMS] Hyderabad, and the samples of the volunteers were sent for labs for study.
After India's apex medical body Indian Council of Medical Research(ICMR) gives its nod, the third phase of the clinical trials will be started.
The drug development firm headquartered in Hyderabad took to Micro-blogging site Twitter and said they are proud to announce the results of the animal trials of the COVAXIN.
âBharat Biotech proudly announces the animal study results of COVAXIN - These results demonstrate the protective efficacy in a live viral challenge model,â the firm's Tweet read.
Bharat Biotech and the Indian Council of Medical Research (ICMR) joined hands to manufacture a vaccine named COVAXIN. 12 Institutions across India were picked to carry out the clinical trials.
To get accurate data on the efficiency of the vaccine, Bharat Biotech International Limited has picked twenty macaques for the Animal trials. These macaques were divided into four groups with five macaques in each group.
It is believed that the vaccine candidate has resulted in generating robust immune system. The system helps in preventing the infection of the virus.
On the other hand, the pandemic vaccine was given to ten more volunteers in Nizam's Institute of Medical Sciences - [NIMS] Hyderabad, and the samples of the volunteers were sent for labs for study.
After India's apex medical body Indian Council of Medical Research(ICMR) gives its nod, the third phase of the clinical trials will be started.